ICAAC 2009
ICAAC 2009: Antiretroviral Pregnancy Registry Indicates Use of Tenofovir (Viread) by Pregnant Women Does Not Raise Risk of Birth Defects
- Details
- Category: Pregnancy & HIV MTCT
- Published on Tuesday, 15 September 2009 13:48
- Written by Liz Highleyman
Data submitted to the Antiretroviral Pregnancy Registry (APR), which collects reports of adverse events associated with use of antiretroviral drugs by HIV positive women during pregnancy, show no link between use of tenofovir (Viread, also in the Truvada and Atripla coformulation) and congenital abnormalities, according to a presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009) this week in San Francisco.
ICAAC 2009: HIV Positive People May Respond Poorly to Pegylated Interferon without Ribavirin for Acute Hepatitis C
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 15 September 2009 13:48
- Written by Liz Highleyman
Pegylated interferon alone may not be adequate for treatment of acute hepatitis C virus (HCV) infection in HIV positive individuals, and addition of ribavirin "seems necessary" for coinfected patients, according to a small study reported at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009) this week in San Francisco.
CROI 2009: Elevated Rate of Heart Attacks and Strokes in HIV Patients on HAART Begins to Decline at California Kaiser Permanente
- Details
- Category: Cardiovascular Disease
- Published on Friday, 13 March 2009 13:57
- Written by Liz Highleyman
As HIV positive people began to live longer thanks to the development of effective antiretroviral therapy, cardiovascular disease became a growing concern, especially given evidence that HIV infection itself and the drugs used to treat it can increase cardiovascular risk.
ICAAC 2009: Resistance to Hepatitis B Drugs is Common among HIV-HBV Coinfected Patients Receiving Lamivudine-containing ART without Tenofovir (Viread)
- Details
- Category: HIV/HBV Coinfection
- Published on Tuesday, 15 September 2009 13:48
- Written by Liz Highleyman
Resistance to the hepatitis B drugs adefovir (Hepsera), entecavir (Baraclude), and telbivudine (Tyzeka) is common among HIV-HBV coinfected individuals treated with antiretroviral therapy (ART) regimens that include lamivudine (3TC; Epivir) without tenofovir (Viread, also in the Truvada and Atripla coformulations), according to a poster presented at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009) this week in San Francisco. These findings support the recommendation that coinfected patients should be treated with ART regimens containing at least 2 drugs with dual activity against HIV and HBV.
Web Design and Development by